Outcomes of CAR-T in relapsed/refractory Myeloma with Severe Renal Dysfunction: A Propensity-Matched Analysis

Key Points

• CAR-T therapy shows improved outcomes in patients with severe renal dysfunction and relapsed myeloma, with a notable response rate.
• In a matched analysis of 30 patients, the overall survival rate was significantly higher in those receiving CAR-T treatment.
• This propensity-matched analysis involved comparisons based on clinical characteristics to adjust for biases, improving outcome validity.
• Future studies need to confirm these findings in more diverse populations to enhance understanding of CAR-T's impact in renal dysfunction cases.